3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Paclitaxel
41
Specimen Handling
36
Carboplatin
34
pembrolizumab
32
Bevacizumab
32
Magnetic Resonance Spectroscopy
29
olaparib
19
liposomal doxorubicin
16
Cisplatin
16
Biopsy
16
Gemcitabine
15
Taxes
12
Nivolumab
12
Immunoglobulin G
11
Disulfides
11
Cyclophosphamide
11
Topotecan
10
Doxorubicin
10
fludarabine
9
niraparib
7
mirvetuximab soravtansine
7
Fulvestrant
7
trastuzumab deruxtecan
6
palbociclib
6
durvalumab
6
Surveys and Questionnaires
6
Megestrol Acetate
6
lenvatinib
5
dostarlimab
5
Radiation
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Blood Component Removal
×
Gynecologic
×
30 days
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled